1322645-32-8
Chemical Structure
VGD020
- CAS No.: 1322645-32-8
- Formula:C31H45N3O5S2
- Molecular Weight:603.84
InChIKey: IADINMLQCKJBSG-UHFFFAOYSA-N
SMILES: O=S(C1=CC=C(C=C1)OC)(N2CC(CN(S(=O)(C3=CC=C(C)C=C3)=O)CCCN(CC4CCCCC4)CCC2)=C)=O
Biological Activity: VGD020 is a highly potent and selective Sec61 translocon inhibitor. VGD020 suppresses the expression of cell surface CD4 by inhibiting signal peptide-dependent co-translational ER translocation, interferes with the initiation of ER translocation of dengue virus polyprotein, and reduces the expression of Sortilin in breast cancer cells. VGD020 exhibits broad anti-flavivirus and anti-HIV activities. VGD020 can be used in research related to dengue virus infection, Zika virus infection, yellow fever virus infection, human immunodeficiency virus infection, and breast cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
VGD020 | VGD020 is a highly potent and selective Sec61 translocon inhibitor. VGD020 suppresses the expression of cell surface CD4 by inhibiting signal peptide-dependent co-translational ER translocation, interferes with the initiation of ER translocation of dengue virus polyprotein, and reduces the expression of Sortilin in breast cancer cells. VGD020 exhibits broad anti-flavivirus and anti-HIV activities. VGD020 can be used in research related to dengue virus infection, Zika virus infection, yellow fever virus infection, human immunodeficiency virus infection, and breast cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
[1]. Verhaegen M, et al. Sec61 translocon inhibitor flavitransin blocks selectively dengue virus polyprotein insertion in the ER with pan-orthoflavivirus antiviral potency. Cell Rep. 2025 Dec 23;44(12):116642.
[Content Brief] - [2]. Berger K, et al. Reduction of Progranulin-Induced Breast Cancer Stem Cell Propagation by Sortilin-Targeting Cyclotriazadisulfonamide (CADA) Compounds. J Med Chem. 2021;64(17):12865-12876. [Content Brief]
- [3]. Demillo VG, et al. Unsymmetrical cyclotriazadisulfonamide (CADA) compounds as human CD4 receptor down-modulating agents. J Med Chem. 2011;54(16):5712-5721. [Content Brief]
Keywords
